Targeted modified IL-2 (NHS-IL2, MSB0010445) combined with stereotactic body radiation in advanced melanoma patients after progression on ipilimumab: Assessment of safety, clinical, and biologic activity in a phase 2a study.
Howard L Kaufman
Consultant or Advisory Role - EMD Serono
Janice M. Mehnert
No relevant relationships to disclose
Jean-Marie Cuillerot
Employment or Leadership Position - EMD Serono
Stock Ownership - Bristol-Myers Squibb
Anja von Heydebreck
Employment or Leadership Position - Merck KGaA
Stock Ownership - Merck KGaA
Patrick Alexander Ott
No relevant relationships to disclose
F. Stephen Hodi
Consultant or Advisory Role - EMD Serono